Business Context and Reporting Period
This Form 8-K Current Report was filed by Becton, Dickinson and Company (BD) on March 16, 2022. The filing primarily addresses corporate governance actions related to the proposed spin-off of BD's diabetes care business into a new entity, Embecta Corp.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The document focuses on capital structure adjustments rather than operational financial results.
Material Changes
- Issuance of Preferred Stock: On March 16, 2022, BD filed a Certificate of Designation for Series C Junior Participating Redeemable Preferred Stock.
- Stock Exchange Transaction: On March 17, 2022, BD issued an aggregate of 3.47883 shares of Series C Preferred Stock to specific Exchange Parties (Trusts under BD's deferral plans). This was done in exchange for 100,000 shares of BD Common Stock per Preferred Share issued.
- Purpose of Exchange: The transaction ensures that the Exchange Parties do not receive shares of Embecta Corp. upon the completion of the Spin-off Transaction.
- Redemption Terms: The Preferred Shares are redeemable at BD's option for Embecta Common Stock. If the Spin-off is completed, the shares will automatically be redeemed for BD Common Stock at a specified rate.
Guidance, Outlook, and Risks
- Spin-off Transaction: BD announced details regarding the proposed distribution of 100% of Embecta Corp. common stock to BD shareholders. This includes information on "when-issued" trading for Embecta and "ex-distribution" trading for BD common stock.
- Regulatory Compliance: The issuance of Preferred Shares relied on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933.
- Unusual Items: The filing notes the creation of a new class of preferred stock specifically designed to manage the mechanics of the corporate spin-off.
Investor Verification Checklist
- Verify the specific redemption rate for Series C Preferred Stock as detailed in the attached Certificate of Designation (Exhibit 3.1).
- Confirm the timeline and conditions for the automatic redemption of Preferred Shares upon the completion of the Embecta spin-off.
- Review the March 21, 2022 press release (Exhibit 99.1) for specific dates regarding "when-issued" and "ex-distribution" trading.
- Assess the impact of the spin-off on the remaining BD business segments and future dividend policies.